

Nanoparticle-based Vaccines against Respiratory Viruses

Soultan Al-Halifa^{1,2}, Laurie Gauthier^{1,2,3,4}, Dominic Arpin^{1,2,3,4}, Steve Bourgault^{1,2,4,*} and Denis Archambault^{3,4,*}

¹Department of Chemistry, Université du Québec à Montréal, Montréal, Canada

²Quebec Network for Research on Protein Function, Engineering and Applications, PROTEO, Québec, Canada

³Department of Biological Sciences, Université du Québec à Montréal, Montréal, Canada

⁴Swine and Poultry Infectious Diseases Research Center, Faculty of Veterinary Medicine, Université de Montréal, St-Hyacinthe, Canada

*Correspondence: Denis Archambault, archambault.denis@uqam.ca and Steve Bourgault, bourgault.steve@uqam.ca

Keywords: Respiratory viruses, Nanocarriers, Nanovaccine, Mucosal sites, Immune response

22 **1. Abstract**

23 The respiratory mucosa is the primary portal of entry for numerous viruses such as the
24 respiratory syncytial **virus**, the influenza **virus** and the parainfluenza virus. These pathogens
25 initially infect the upper respiratory tract and then reach the lower respiratory tract, leading to
26 diseases. Vaccination is an affordable way to control the pathogenicity of viruses and constitutes
27 the strategy of choice to fight against infections, including those **leading to pulmonary diseases**.
28 Conventional vaccines based on live-attenuated pathogens present a risk of reversion to pathogenic
29 virulence while inactivated pathogen vaccines often lead to a weak immune response. Subunit
30 vaccines were developed to overcome these issues. However, these vaccines may suffer from a
31 limited immunogenicity and, in most cases, the protection induced is only partial. A new
32 generation of vaccines based on nanoparticles has shown great potential to address most of the
33 limitations of conventional and subunit vaccines. This is due to recent advances in chemical and
34 **biological** engineering, which allow the design of nanoparticles with a precise control over the
35 size, shape, functionality and surface properties, leading to **enhanced** antigen presentation and
36 strong immunogenicity. This short review provides an overview of the advantages associated with
37 the use of nanoparticles **as vaccine delivery platforms to immunize** against respiratory viruses and
38 highlights relevant examples demonstrating their potential as safe, effective and affordable
39 vaccines.

40

41

42 **1. Introduction**

43 Lower respiratory tract infections (LRTIs) constitute a major public health burden worldwide.
44 LRTIs represent a leading cause of human mortality and morbidity, causing annually over 3
45 million deaths worldwide (World Health Organization, 2016). Among these infections, about 80%
46 of LRTIs cases are caused by viruses (Seo et al., 2014). In most cases, these pathogens enter the
47 host via airborne transmissions (e.g. droplets or aerosols), replicate efficiently in the respiratory
48 tract and cause clinical manifestations, ranging from fever to bronchiolitis and pneumonia (Kutter
49 et al., 2018). In addition, LRTIs associated with viruses represent an important source of economic
50 loss for livestock and poultry industry as these infections predispose animals to secondary bacterial
51 infections (Griffin, 1997; Taylor et al., 2010; Johnson and Pendell, 2017).

52
53 Viruses infecting the human lower respiratory tract include the influenza virus, the respiratory
54 syncytial virus (RSV), the parainfluenza virus and the adenovirus (Walker et al., 1994; Pavia,
55 2011). Seasonal influenza [virus](#) epidemics result in a significant burden of disease in children and
56 elderly and account for 3 to 5 million cases of severe illness and for nearly 290 000 to 650 000
57 deaths worldwide each year (World Health Organization, 2018). RSV and parainfluenza [virus](#)
58 infections are the leading cause of hospitalization for acute respiratory infections in young
59 children, causing 45% and 40% of pediatric hospitalizations, respectively (Branche and Falsey,
60 2016; Mazur et al., 2018). Adenovirus infections account for 3 to 5% of LRTIs cases in children
61 and can be fatal for immunocompromised patients (Lu et al., 2013). In general, respiratory viruses
62 represent a major health problem in infants, young children, immunocompromised patients and
63 the elderly population. According to Global Burden of Diseases (GBD), 74% of deaths associated
64 with LRTIs represent these vulnerable patient groups (Collaborators, 2017).

65

66 Vaccination remains the most cost-effective [strategy](#) to fight against infectious diseases.
67 Conventionally, vaccine formulations consist of attenuated viruses, killed pathogens (inactivated)
68 or subunit protein antigens, which elicit a specific immune response. These vaccine formulations
69 have allowed the prevention, [or the control](#), of several important diseases including rubella, yellow
70 fever, polio and measles, and, in the case of smallpox, even eradication (Fenner et al., 1988;Hajj
71 Hussein et al., 2015). Considerable efforts have been devoted for the development of efficient
72 vaccines against LRTIs, including inactivated/fragmented trivalent or quadrivalent seasonal
73 vaccines against influenza type A and type B viruses such as Influvac® (Daubeney et al., 1997),
74 Vaxigrip® (Delore et al., 2006) and Fluzone® (Grohskopf et al., 2015) as well as live attenuated
75 vaccines such as Nasovac® and Flumist® for nasal administration in young children (Carter and
76 Curran, 2011;Dhere et al., 2011). Nevertheless, live-attenuated vaccines against influenza [virus](#)
77 suffer from safety concerns due to their nature and represent a risk for elderly and
78 immunosuppressed humans (Chattopadhyay et al., 2017). Besides, killed pathogen vaccines and
79 virus-derived subunit vaccines induce weaker immune responses and often require the use of
80 strong adjuvant to boost efficiency (Vartak and Sucheck, 2016).

81

82 Several promising vaccines are currently evaluated in the clinics for different respiratory
83 viruses (Papadopoulos et al., 2017). These new vaccine formulations aim to be safer and more
84 efficient [compared to traditional vaccines based on attenuated viruses, killed pathogens and](#)
85 [subunits](#). Nevertheless, the high level of antigenic drift (genetic mutations) of some viruses, such
86 as the influenza virus, reduces the efficacy of vaccines and needs to be addressed (Boni, 2008).
87 Therefore, while improving safety and efficiency, vaccines should also be less sensitive to

88 antigenic drift. The **concept of** “universal vaccine” is **critical** for viruses like **the** influenza virus,
89 and new formulations to induce broad-spectrum immunity are being investigated. In the next
90 sections, we discuss the advantages of using nanoparticle formulations against respiratory viruses
91 and we highlight relevant examples of the use of nanoparticles as safe, effective and affordable
92 vaccines.

93

94 **2. Nanoparticles, an alternative approach to conventional vaccines**

95 The use of particles as nanopatforms displaying relevant antigenic moieties is appealing as
96 an alternative **approach** to conventional vaccines. These nano-sized materials can be obtained from
97 biological sources and/or can be synthetic. Currently, there is a large variety of particles evaluated
98 as antigen carriers, including, inorganic and polymeric-nanoparticles, virus-like particles (VLPs),
99 liposomes and self-assembled protein nanoparticles (**Figure 1A**). The **advantages** of these
100 materials reside primarily in their size (at least one dimension should be at the nanometer level),
101 since many biological systems such as viruses and proteins are nano-sized (Laval et al., 2000).
102 Nanoparticles can be administered via sub-cutaneous and intramuscular injections, or can be
103 delivered through the mucosal sites (oral and intranasal), and penetrate capillaries as well as
104 mucosal surfaces (Parveen et al., 2016;Schneider et al., 2017). Recent progresses have allowed the
105 preparation of nanoparticles with unique physicochemical properties. For instance, size, shape,
106 solubility, surface chemistry and hydrophilicity can be tuned and controlled, which allows the
107 preparation of nanoparticles with tailored biological properties (Angioletti-Uberti, 2017).
108 Moreover, nanoparticles can be designed to allow the incorporation of a wide range of molecules
109 including antigens which makes them highly interesting in vaccinology (Irvine et al., 2015;Szeto
110 and Lavik, 2016).

111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132

Incorporation of antigens in nanoparticles can be achieved by encapsulation (physical entrapment) or by conjugation (covalent functionalization) (Chattopadhyay et al., 2017). Studies have demonstrated that nanoparticles could protect the native structure of antigens from proteolytic degradation and/or improve antigen delivery to antigen-presenting cells (APCs) (Pachioni-Vasconcelos Jde et al., 2016). In addition, nanoparticles incorporating antigens can exert a local depot effect, ensuring prolonged antigen presentation to immune cells (Fredriksen and Grip, 2012). Interestingly, nanoparticles have also shown intrinsic immunomodulatory activity (Mamo and Poland, 2012). For instance, nanoparticles such as carbon nanotubes (CNTs), carbon black nanoparticles, poly(lactic-co-glycolic acid) (PLGA) and polystyrene nanoparticles, titanium dioxide (TiO₂) nanoparticles, silicon dioxide (SiO₂) nanoparticles, and aluminum oxyhydroxide nanoparticles have been reported to induce NLRP3-associated inflammasome activation (Zhu et al., 2014). In fact, once internalized by APCs, these nanoparticles provide signals that trigger lysosomal destabilization and the production of reactive oxygen species (ROS), leading to the release of lysosomal contents, including the cysteine protease cathepsin B. This protease is sensed by NLRP3, which subsequently activates the formation of the inflammasome complex (Ghiringhelli et al., 2009;Tschopp and Schroder, 2010;Bruchard et al., 2012;Abderrazak et al., 2015;He et al., 2016). Subsequently, interleukins are produced as downstream signaling events, leading to the recruitment and/or activation of immune cells (Cassel et al., 2008;Halle et al., 2008;Ghiringhelli et al., 2009;Sharp et al., 2009;Masters et al., 2010;Niemi et al., 2011;Scharf et al., 2012). Taken together, these properties advocate that nanoparticles are promising antigen carriers and immune cell activators for vaccination.

133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155

3. Nanoparticles and the respiratory tract immune system

The respiratory mucosa represents the primary site for invasion and infection by a virus whose replication occurs in the ciliated cells of the upper respiratory tract (URT). Subsequently, infection spreads to the low respiratory tract (LRT) by virus-rich secretions and by infected cell debris from the URT (Adair, 2009). Nasal-associated lymphoid tissue (NALT), the first site for inhaled antigen recognition located in the URT, is an important line of defense against respiratory viruses. NALT is present in rodents, birds and primates (Kang et al., 2014). This structure is characterized by aggregates of lymphoid cells located in the nasopharyngeal cavity (Marasini et al., 2017). In human, the Waldever's ring, made of adenoid and tonsil, is considered as the equivalent of NALT structure, which contains various narrow epithelial channels. NALT comprises aggregates of lymphoid follicles (B-cell areas), interfollicular areas (T-cell areas), macrophages and dendritic cells (DCs) (Figure 1B), which, when activated, support the clearance of infectious agents (Zuercher et al., 2002;Adair, 2009;Marasini et al., 2017). Accordingly, NALT is considered as an inductive site for humoral and cellular immune responses and represents a promising target for vaccines against respiratory viruses. Ideally, nanovaccines would follow a path similar to respiratory viruses in order to efficiently deliver antigens to NALT and trigger a specific mucosal immune response. Therefore, formulation, size and antigen exposition are critical aspects when designing nanovaccines targeting NALT. Most respiratory viruses have an average diameter size ranging between 20 and 200 nm (Lamb and Choppin, 1983;Henrickson, 2003;Utlely et al., 2008;Hall et al., 2010). Thus, besides being safe and immunogenic on its own, a nanovaccine should have a size similar to viruses while incorporating relevant antigens (Gomes et al., 2017).

156 Over the last decade, a number of nanoparticles have been designed to mimic respiratory
157 viruses in terms of size, shape and surface property in order to target NALT as well as to raise
158 humoral and cellular immune responses (Niu et al., 2013;Chattopadhyay et al., 2017;Fogarty and
159 Swartz, 2018). First, beside a nanoparticle size of 20 to 200 nm in diameter to match the size of
160 most respiratory viruses, nanoparticles should be [preferably](#) positively charged. In fact, positively
161 charged polymeric, phospholipidic, metallic, inorganic and protein-based nanoparticles have
162 shown stronger immune responses compared to their negatively charged [counterparts](#) (Fromen et
163 [al., 2015;Chattopadhyay et al., 2017](#)). Second, the incorporation of antigens/epitopes within or on
164 the surface of the nanoparticles can be challenging and requires advanced approaches in chemical
165 and/or biological engineering (Chattopadhyay et al., 2017). The most common strategy is to
166 encapsulate or entrap antigens/epitopes within the nanoparticles. In this case, nanoparticles are
167 used to protect the antigen/epitopes and deliver them to NALT (Rahimian et al., 2015;Kasturi et
168 al., 2017;Kishimoto and Maldonado, 2018). Nanoencapsulation can be achieved by using different
169 procedures, including nanoprecipitation and oil in water (o/w) emulsion (Kumari et al., 2014).
170 Alternatively, antigens can be attached and exposed on the nanoparticle surface. This strategy aims
171 at mimicking viruses. Conjugation of antigenic epitope can be performed directly on the
172 nanoparticles using different chemical reactions like the disulfide bonding and the thiolate-gold
173 bond formation (Hirosue et al., 2010;Ding et al., 2017;Tao et al., 2017). Otherwise, it can be
174 achieved by first preparing an epitope-functionalized self-assembling unit, which upon self-
175 assembly form nanoparticles decorated with the antigen (Mora-Solano et al., 2017;Negahdaripour
176 et al., 2017;Babych et al., 2018). Third, the formulation and administration strategies are also
177 critical [aspects to consider](#). Vaccines administered via subcutaneous or intramuscular injection
178 induce systemic immunity and usually, a weak mucosal response is observed. On the other hand,

179 mucosal vaccination, either oral or intranasal delivery, induces humoral and cellular immune
180 responses at the systemic level and the mucosal surfaces, which is more effective in the protection
181 against respiratory viruses (Ichinohe et al., 2009;Lycke, 2012). Studies have demonstrated that
182 vaccination via the intranasal route provides a better protection when compared to subcutaneous
183 immunization in the context of respiratory pathogens and mucosal immunity. Intranasal
184 vaccination led to higher antigen-specific lymphocyte proliferation, [cytokine production](#)
185 [\(interferon- \$\gamma\$, interleukins\)](#) and induction of antigen-specific IgA antibody (Chen et al., 2004;Giri
186 et al., 2005;Mapletoft et al., 2010;Kharb and Charan, 2011;McCormick et al., 2018). A promising
187 formulation strategy is the intranasal spray, which delivers conveniently and safely the
188 nanovaccines directly to the respiratory mucosa (Birkhoff et al., 2009;Kanojia et al., 2017;Kim
189 and Jang, 2017). However, the number of clinical trials using nanovaccine formulations for
190 intranasal delivery, including spray dried nanovaccines, is limited. This is [mostly associated with](#)
191 [the difficulty of keeping the nanovaccine integrity during the entire formulation process](#) (Kanojia
192 et al., 2017). [Moreover](#), the immune response is particularly sensitive to the nature, size, shape and
193 surface properties of the nanoparticles as well as to the density and the potency of the antigens.
194 Thus, it is very challenging to predict the effect of a given nanovaccine on the immune system. [In](#)
195 [addition, nanoparticles have some limitations associated with their synthesis, or preparation, and](#)
196 [their properties. These include limited antigen loading, low synthesis yield, poor targeting](#)
197 [capability to immune cells, limited manufacturability, and, in some cases, toxicity](#) (Shao et al.,
198 [2015;Zilker et al., 2017;Pan et al., 2018](#)). [These drawbacks can lead to side effects and/or poor](#)
199 [immunogenicity, which precludes their clinical usage. Besides, little is known about the](#)
200 [interactions between nanoparticles and immune cells. In fact, their adjuvant effect and their ability](#)
201 [to activate the immune system still remain unclear and need to be better understood at the](#)

202 [molecular level](#) (Sahdev et al., 2014). Nonetheless, nanoparticle formulations have recently
203 revealed promising results against respiratory virus infections (**Table 1**) and relevant examples
204 will now be discussed.

205

206 **4. Polymeric nanoparticles**

207 A polymer consists of a large molecule constructed from monomeric units. Depending on the
208 construction, polymers can be linear, slightly branched or hyperbranched (3D network) (Piluso et
209 al., 2017). Polymeric nanoparticles can be either obtained from the polymerization of monomeric
210 units or from preformed polymers. These nanoparticles are attractive in the medical field due to
211 their adjustable properties (size, composition and surface properties), which allow controlled
212 release, ability to combine both therapy and imaging (theranostics), and protection of drug
213 molecules (Kamaly et al., 2012;Krasia-Christoforou and Georgiou, 2013;Tang et al., 2016). For
214 example, poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer
215 approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for
216 use in humans. This is due to its ability to undergo hydrolysis *in vivo*, resulting in lactic acid and
217 glycolic acid metabolites, which are efficiently processed by the body (Acharya and Sahoo, 2011).
218 PLGA can be engineered to form nanoparticles capable of encapsulating different types of
219 biomolecules and release them sustainably over time (Acharya and Sahoo, 2011;Mahapatro and
220 Singh, 2011;Danhier et al., 2012;Silva et al., 2016). [These nanoparticles](#) can encapsulate antigens
221 and prevent their degradation over 4 weeks under physiological conditions, which is critical for
222 mucosal vaccination (Getts et al., 2015). Moreover, PLGA-NPs [promote](#) antigen internalization
223 by APCs and facilitate antigen processing and presentation to naïve lymphocytes (Woodrow et al.,
224 2012;Santos et al., 2013). [For instance, spherical PLGA-NPs \(200 to 300 nm of diameter\)](#) were

225 used to encapsulate an inactivated Swine influenza virus (SwIV) H1N2 antigens (KAg) via
226 water/oil/water double emulsion solvent evaporation (Dhakal et al., 2017). It was observed that
227 pigs vaccinated twice with this preparation and challenged with a virulent heterologous influenza
228 virus strain, have a significantly milder disease in comparison to non-vaccinated animals. This
229 observation correlated closely with the reduced lung pathology and the substantial clearance of the
230 virus from the animal lungs. Other polymeric nanoparticles, such as chitosan a natural polymer
231 composed of randomly distributed β -(1-4)-linked d-glucosamine and N-acetyl-d-glucosamine, and
232 N-(2-hydroxypropyl)methacrylamide/N-isopropylacrylamide (HPMA/NIPAM), were also
233 investigated as intranasal vaccines against respiratory viruses (Csaba et al., 2009;Li et al., 2014a;Li
234 et al., 2014b;Sawaengsak et al., 2014;Liu et al., 2015;Lynn et al., 2015;Francica et al., 2016;Islam
235 et al., 2016;Marasini et al., 2016;Wu et al., 2017;Dabaghian et al., 2018;Dhakal et al., 2018;Zhang
236 et al., 2018). Polymeric nanoparticles have many advantages, including biocompatibility (Vela-
237 Ramirez et al., 2015), antigen encapsulation and stabilization (Carrillo-Conde et al., 2010;Petersen
238 et al., 2012), controlled release of antigens and intracellular persistence in APCs (Ulery et al.,
239 2011a;Ulery et al., 2011b), pathogen-like characteristics, and suitability for intranasal
240 administration (Ulery et al., 2011b;Ross et al., 2014). Nevertheless, the effect of the [polymer](#)
241 [properties](#) (core chemistry, size, shape, surface properties) on the transport within the URT remains
242 unknown. More studies are needed to better understand the effect of changing nanoparticle
243 properties on their [biological activities](#) and to, ultimately, predict the fate of these nanocarriers
244 upon their intranasal administration.

245

246 **5. Self-assembling protein nanoparticles and VLPs**

247 Self-assembling protein nanoparticles (SAPNs) are structures obtained from the
248 oligomerization of monomeric proteins. [The protein building blocks are mostly obtained through](#)
249 [recombinant technologies](#) and are considered safe for biomedical applications (Scheerlinck and
250 Greenwood, 2008). SAPNs can be engineered to have a diameter ranging from 20 to 100 nm,
251 similar to the sizes of many viruses [and therefore, are considered as potential nanovaccine](#)
252 [candidates against viruses, including respiratory viruses](#) (Scheerlinck and Greenwood,
253 2008;Schneider-Ohrum and Ross, 2012). For example, SANPs, designed [to elicit an immune](#)
254 [response](#) against RSV, have been explored using the nucleoprotein (N) from the virus
255 nucleocapsid. N is a major target of antigen-specific cytotoxic T-cell response. The self-assembly
256 of N-protein protomers led to the formation of supramolecular nanorings of 15 nm diameter (Roux
257 et al., 2008). This platform was modified by fusing the FsII epitope targeted by monoclonal
258 neutralizing antibody (palivizumab) to the N-protein, in order to form chimeric nanorings with
259 enhanced immune response and virus protection against RSV. The results showed reduced virus
260 load in the lungs of challenged mice (Herve et al., 2017). [Similarly](#), chimeric nanorings displaying
261 3 repeats of the highly conserved ectodomain of the influenza virus A matrix protein 2 (M2e),
262 were prepared by recombinant technologies (Herve et al., 2014). When administrated [via](#) the
263 intranasal route, these M2e-functionalized nanorings induced local production of mucosal
264 antibodies and led to mice protection (Herve et al., 2014). These N-nanorings are interesting for
265 intranasal delivery of antigen due to their similarities with respiratory viruses in term of size and
266 structure (sub-nucleocapsid-like superstructures). Other examples of SAPNs as potential
267 nanovaccines against respiratory viruses include the capsid protein of the papaya mosaic virus
268 (PapMV), [the purified coronavirus spike protein](#) and ferritin, which are self-assembling proteins

269 that form rod-shaped and nearly spherical nanostructures, respectively (Lawson et al., 1991;Lee
270 and Wang, 2006;Li et al., 2006;Yamashita et al., 2010;Yang et al., 2012;Babin et al.,
271 2013;Kanekiyo et al., 2013;Coleman et al., 2014;Lopez-Sagaseta et al., 2016;Park et al.,
272 2017;Therien et al., 2017;Qi et al., 2018). Recently, assemblies composed of four tandem copies
273 of M2e and headless HA proteins were prepared and stabilized by sulfosuccinimidyl propionate
274 crosslinking, showing the possibility of generating protein nanoparticles almost entirely composed
275 of the antigens of interest (Deng et al., 2018).

276

277 VLPs are spherical supramolecular assemblies of 20 to 200 nm diameter, which result from the
278 self-assembly of viral capsid proteins. These particles are free from genetic materials and have the
279 advantage of mimicking perfectly the structure and the antigenic epitopes of their corresponding
280 native viruses. Therefore, this repetitive antigen display promotes efficient phagocytosis by APCs
281 and subsequent activation (Kushnir et al., 2012;Mathieu et al., 2013;Zeltins, 2013;Zhao et al.,
282 2013;Mohsen et al., 2017). Recently, Lee and colleagues demonstrated that intranasal delivery of
283 influenza-derived VLPs expressed in insect cells and exposing 5 repeats of the M2e epitopes,
284 confers cross protection against different serotypes of influenza viruses by inducing humoral and
285 cellular immune responses (Lee et al., 2018).

286

287 SAPNs and VLPs are thus attractive but their formulation into stable and spray dried vaccines
288 for intranasal injection can be challenging and may require the use of surfactants and saccharides
289 (Lang et al., 2009). In the last decades, self-assembling peptides (SAPs) have also been
290 investigated as intranasal nanovaccines against respiratory viruses due to their straightforward
291 chemical synthesis and their storage stability upon lyophilization (Si et al., 2018).

292

293 **6. Inorganic nanoparticles**

294 There are many inorganic nanoparticles suitable for biomedical applications, including
295 superparamagnetic nanoparticles (iron oxide nanoparticles), quantum dots and plasmonic
296 nanoparticles (gold and silver nanoparticles). Inorganic materials are mostly used as tools with
297 improved therapeutic efficacy, biodistribution and pharmacokinetics. However, inherently, plain
298 inorganic core nanoparticles would not be suitable in biological fluids due to particle aggregation.
299 Therefore, in the medical field, these nanoparticles are often coated with organic molecules via
300 adsorption or chemical reactions. In fact, these biocompatible nanoparticles can be described as
301 complex hybrids materials with an inorganic **core** and an organic outer shell (Feliu et al.,
302 2016;Giner-Casares et al., 2016). Among inorganic nanoparticles, the most commonly used **for**
303 vaccination are gold nanoparticles (AuNPs). AuNPs are readily internalized by macrophages and
304 dendritic cells, and induce their activation (Bastus et al., 2009;Kang et al., 2017). Large scale
305 production is possible with strict control on particle size and ease of functionalization using the
306 strong affinity between thiol groups and gold. Thiol groups can be attached to AuNP surface by
307 forming thiolate–Au bonds (Hiramatsu and Osterloh, 2004;Pensa et al., 2012;Spampinato et al.,
308 2016;Belmouaddine et al., 2018). Furthermore, no immune response is elicited towards inert
309 carriers like AuNPs (Wang et al., 2018). Thus, these nanoparticles are an appealing platform for
310 nanovaccine engineering *via* antigen functionalization.

311

312 A wide range of molecules, including adjuvants and antigens can be conjugated on AuNPs at
313 high density, resulting in improved immunogenicity and antigen presentation (Cao-Milan and Liz-
314 Marzan, 2014;Jazayeri et al., 2016). AuNPs can be formulated for intranasal administration and

315 can diffuse into the lymph nodes, triggering robust antigen-specific cytotoxic T-cell immune
316 responses (Salazar-Gonzalez et al., 2015; Marques Neto et al., 2017). Tao and coworkers have
317 demonstrated that the peptide consensus M2e of influenza A viruses with a non-native cysteine
318 residue at the C-terminal end could be attached on the AuNPs via thiolate–Au chemistry. The
319 resulting M2e-AuNPs was administered by the intranasal route to mice with CpG (cytosine-
320 guanine rich oligonucleotide) adjuvant, triggering a fully protective immune response against the
321 influenza virus PR8 strain (Tao et al., 2014). More recently, it was demonstrated that this
322 formulation could induce lung B cell activation and robust serum anti-M2e IgG response, with
323 stimulation of both IgG1 and IgG2a subclasses (Tao et al., 2014). Additionally, this vaccination
324 strategy led to protection against infection by the pandemic influenza virus strain,
325 A/California/04/2009 (H1N1pdm) pandemic strain, influenza virus A/Victoria/3/75 (H3N2) strain
326 and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) (Tao et al., 2017).
327 Although gold nanoparticles constitute an attractive platform for antigen conjugation, they can
328 accumulate in organs such as liver and spleen for a long period, which could be ultimately
329 associated with toxicity (Boisselier and Astruc, 2009). Coating with biocompatible materials
330 reduces their toxicity, although it can lead to alterations of the physicochemical and biological
331 properties. Therefore, safety issues of AuNPs still need to be addressed.

332

333 7. Conclusion and perspectives

334 Engineered nanoparticles have demonstrated their potential as vaccine delivery platforms.
335 They can be envisaged as both antigen nanocarriers and adjuvants. In all cases, intranasal
336 administration of nanovaccines allows a convenient and safe delivery of the antigen to NALT,
337 inducing mucosal and systemic immunity. Nonetheless, additional studies are still needed before

338 their clinical translation. While intranasal vaccination of nanoparticles generates specific IgA
339 antibody in the URT and leads to high survival rates in animal models, there are still limited studies
340 on nonhuman primates, thus making nanoparticle's fate difficult to predict **in a human URT**. In
341 addition, nanoparticle vaccines are generally functionalized with specific antigen(s), which result
342 in an immune response **targeted** against these antigenic determinants. Considering antigenic drifts,
343 the **growing human population** that needs to be vaccinated and the different type of viruses, the
344 cost to address all these aspects would be too **prohibitive** to produce affordable vaccines.
345 **Consequently, the development of broad spectrum vaccines constitutes a critical need and we**
346 **consider that nanovaccine engineering will contribute to achieve this objective.**

347

348 **8. Acknowledgments**

349 This work was supported by grants from the Natural Sciences and Engineering Research Council
350 of Canada (NSERC) and the International Development Research Centre (IDRC) to D.
351 Archambault and S. Bourgault.

352

353 **9. Author Contributions Statement**

354 All authors have participated in writing and preparation of the manuscript, and approved it for
355 publication.

356 **10. Conflict of interest Statement**

357 The authors declare that the research was conducted in the absence of any commercial or financial
358 relationships that could be construed as a potential conflict of interest.

359

360 11. References

- 361 Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., and Rouis, M. (2015). NLRP3
362 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and
363 inflammatory diseases. *Redox Biology* 4, 296-307.
- 364 Acharya, S., and Sahoo, S.K. (2011). PLGA nanoparticles containing various anticancer agents and tumour
365 delivery by EPR effect. *Adv Drug Deliv Rev* 63, 170-183.
- 366 Adair, B.M. (2009). Nanoparticle vaccines against respiratory viruses. *Wiley Interdiscip Rev Nanomed*
367 *Nanobiotechnol* 1, 405-414.
- 368 Angioletti-Uberti, S. (2017). Theory, simulations and the design of functionalized nanoparticles for
369 biomedical applications: A Soft Matter Perspective. *npj Computational Materials* 3, 48.
- 370 Babin, C., Majeau, N., and Leclerc, D. (2013). Engineering of papaya mosaic virus (PapMV) nanoparticles
371 with a CTL epitope derived from influenza NP. *J Nanobiotechnology* 11, 10.
- 372 Babych, M., Bertheau-Mailhot, G., Zottig, X., Dion, J., Gauthier, L., Archambault, D., and Bourgault, S.
373 (2018). Engineering and evaluation of amyloid assemblies as a nanovaccine against the
374 Chikungunya virus. *Nanoscale*.
- 375 Bastus, N.G., Sanchez-Tillo, E., Pujals, S., Farrera, C., Kogan, M.J., Giralt, E., Celada, A., Lloberas, J., and
376 Puentes, V. (2009). Peptides conjugated to gold nanoparticles induce macrophage activation. *Mol*
377 *Immunol* 46, 743-748.
- 378 Belmouaddine, H., Shi, M., Sanche, L., and Houde, D. (2018). Tuning the size of gold nanoparticles
379 produced by multiple filamentation of femtosecond laser pulses in aqueous solutions. *Phys*
380 *Chem Chem Phys* 20, 23403-23413.
- 381 Birkhoff, M., Leitz, M., and Marx, D. (2009). Advantages of Intranasal Vaccination and Considerations on
382 Device Selection. *Indian Journal of Pharmaceutical Sciences* 71, 729-731.
- 383 Boisselier, E., and Astruc, D. (2009). Gold nanoparticles in nanomedicine: preparations, imaging,
384 diagnostics, therapies and toxicity. *Chem Soc Rev* 38, 1759-1782.
- 385 Boni, M.F. (2008). Vaccination and antigenic drift in influenza. *Vaccine* 26 Suppl 3, C8-14.
- 386 Branche, A.R., and Falsey, A.R. (2016). Parainfluenza Virus Infection. *Semin Respir Crit Care Med* 37, 538-
387 554.
- 388 Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B.,
389 Ryffel, B., Connat, J.L., Kanellopoulos, J., Martin, F., Rébé, C., Apetoh, L., and Ghiringhelli, F.
390 (2012). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells
391 activates the Nlrp3 inflammasome and promotes tumor growth. *Nature Medicine* 19, 57.
- 392 Cai, M., Wang, C., Li, Y., Gu, H., Sun, S., Duan, Y., Lai, C., Wang, K., Yang, X., Xing, L., Zhang, P., Wang, Z.,
393 Zhang, S., Guo, X., Liu, S., Tong, Y., Wang, X., and Yang, P. (2017). Virus-like particle vaccine by
394 intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in
395 mice. *Acta Biochim Biophys Sin (Shanghai)* 49, 74-82.
- 396 Cao-Milan, R., and Liz-Marzan, L.M. (2014). Gold nanoparticle conjugates: recent advances toward
397 clinical applications. *Expert Opin Drug Deliv* 11, 741-752.
- 398 Carrillo-Conde, B., Schiltz, E., Yu, J., Chris Minion, F., Phillips, G.J., Wannemuehler, M.J., and Narasimhan,
399 B. (2010). Encapsulation into amphiphilic polyamphiphilic microparticles stabilizes *Yersinia pestis*
400 antigens. *Acta Biomater* 6, 3110-3119.
- 401 Carter, N.J., and Curran, M.P. (2011). Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of
402 its use in the prevention of seasonal influenza in children and adults. *Drugs* 71, 1591-1622.
- 403 Cassel, S.L., Eisenbarth, S.C., Iyer, S.S., Sadler, J.J., Colegio, O.R., Tephly, L.A., Carter, A.B., Rothman, P.B.,
404 Flavell, R.A., and Sutterwala, F.S. (2008). The Nalp3 inflammasome is essential for the
405 development of silicosis. *Proceedings of the National Academy of Sciences* 105, 9035.

406 Chattopadhyay, S., Chen, J.Y., Chen, H.W., and Hu, C.J. (2017). Nanoparticle Vaccines Adopting Virus-like
407 Features for Enhanced Immune Potentiation. *Nanotheranostics* 1, 244-260.

408 Chen, L., Wang, J., Zganiacz, A., and Xing, Z. (2004). Single intranasal mucosal Mycobacterium bovis BCG
409 vaccination confers improved protection compared to subcutaneous vaccination against
410 pulmonary tuberculosis. *Infect Immun* 72, 238-246.

411 Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., Glenn, G.M., Smith, G.E., and
412 Frieman, M.B. (2014). Purified coronavirus spike protein nanoparticles induce coronavirus
413 neutralizing antibodies in mice. *Vaccine* 32, 3169-3174.

414 Collaborators, G.L. (2017). Estimates of the global, regional, and national morbidity, mortality, and
415 aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the
416 Global Burden of Disease Study 2015. *Lancet Infect Dis* 17, 1133-1161.

417 Coulter, A., Harris, R., Davis, R., Drane, D., Cox, J., Ryan, D., Sutton, P., Rockman, S., and Pearse, M.
418 (2003). Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine. *Vaccine* 21, 946-
419 949.

420 Csaba, N., Garcia-Fuentes, M., and Alonso, M.J. (2009). Nanoparticles for nasal vaccination. *Adv Drug*
421 *Deliv Rev* 61, 140-157.

422 Dabaghian, M., Latifi, A.M., Tebianian, M., Najminejad, H., and Ebrahimi, S.M. (2018). Nasal vaccination
423 with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate
424 systems: Preparation and immunogenicity in a mouse model. *Vaccine* 36, 2886-2895.

425 Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A., and Preat, V. (2012). PLGA-based
426 nanoparticles: an overview of biomedical applications. *J Control Release* 161, 505-522.

427 Daubeney, P., Taylor, C.J., MCGaw, J., Brown, E.M., Ghosal, S., Keeton, B.R., Palache, B., and Kerstens, R.
428 (1997). Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in
429 high-risk children aged 6 months to 4 years. *Br J Clin Pract* 51, 87-90.

430 Delore, V., Salamand, C., Marsh, G., Arnoux, S., Pepin, S., and Saliou, P. (2006). Long-term clinical trial
431 safety experience with the inactivated split influenza vaccine, Vaxigrip. *Vaccine* 24, 1586-1592.

432 Deng, L., Mohan, T., Chang, T.Z., Gonzalez, G.X., Wang, Y., Kwon, Y.M., Kang, S.M., Compans, R.W.,
433 Champion, J.A., and Wang, B.Z. (2018). Double-layered protein nanoparticles induce broad
434 protection against divergent influenza A viruses. *Nat Commun* 9, 359.

435 Dhakal, S., Hiremath, J., Bondra, K., Lakshmanappa, Y.S., Shyu, D.L., Ouyang, K., Kang, K.I., Binjawadagi,
436 B., Goodman, J., Tabynov, K., Krakowka, S., Narasimhan, B., Lee, C.W., and Renukaradhya, G.J.
437 (2017). Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides
438 heterologous cell-mediated immune response in pigs. *J Control Release* 247, 194-205.

439 Dhakal, S., Renu, S., Ghimire, S., Shaan Lakshmanappa, Y., Hogshead, B.T., Feliciano-Ruiz, N., Lu, F.,
440 Hogenesch, H., Krakowka, S., Lee, C.W., and Renukaradhya, G.J. (2018). Mucosal Immunity and
441 Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan
442 Nanoparticle Delivery in Pigs. *Front Immunol* 9, 934.

443 Dhere, R., Yeolekar, L., Kulkarni, P., Menon, R., Vaidya, V., Ganguly, M., Tyagi, P., Barde, P., and Jadhav,
444 S. (2011). A pandemic influenza vaccine in India: from strain to sale within 12 months. *Vaccine*
445 29 Suppl 1, A16-21.

446 Ding, P., Zhang, T., Li, Y., Teng, M., Sun, Y., Liu, X., Chai, S., Zhou, E., Jin, Q., and Zhang, G. (2017).
447 Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a
448 model of porcine circovirus type 2. *Int J Nanomedicine* 12, 5239-5254.

449 Feliu, N., Docter, D., Heine, M., Del Pino, P., Ashraf, S., Kolosnjaj-Tabi, J., Macchiarini, P., Nielsen, P.,
450 Alloyeau, D., Gazeau, F., Stauber, R.H., and Parak, W.J. (2016). In vivo degeneration and the fate
451 of inorganic nanoparticles. *Chem Soc Rev* 45, 2440-2457.

452 Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and its Eradication.
453 *World Health Organization Geneva.*

454 Fogarty, J.A., and Swartz, J.R. (2018). The exciting potential of modular nanoparticles for rapid
455 development of highly effective vaccines. *Current Opinion in Chemical Engineering* 19, 1-8.

456 Francica, J.R., Lynn, G.M., Laga, R., Joyce, M.G., Ruckwardt, T.J., Morabito, K.M., Chen, M., Chaudhuri, R.,
457 Zhang, B., Sastry, M., Druz, A., Ko, K., Choe, M., Pechar, M., Georgiev, I.S., Kuelzto, L.A.,
458 Seymour, L.W., Mascola, J.R., Kwong, P.D., Graham, B.S., and Seder, R.A. (2016).
459 Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.
460 *Bioconjug Chem* 27, 2372-2385.

461 Fredriksen, B.N., and Grip, J. (2012). PLGA/PLA micro- and nanoparticle formulations serve as antigen
462 depots and induce elevated humoral responses after immunization of Atlantic salmon (*Salmo*
463 *salar* L.). *Vaccine* 30, 656-667.

464 Fromen, C.A., Robbins, G.R., Shen, T.W., Kai, M.P., Ting, J.P., and Desimone, J.M. (2015). Controlled
465 analysis of nanoparticle charge on mucosal and systemic antibody responses following
466 pulmonary immunization. *Proc Natl Acad Sci U S A* 112, 488-493.

467 Getts, D.R., Shea, L.D., Miller, S.D., and King, N.J. (2015). Harnessing nanoparticles for immune
468 modulation. *Trends Immunol* 36, 419-427.

469 Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T.,
470 Mignot, G., Ullrich, E., Perfettini, J.-L., Schlemmer, F., Tasdemiir, E., Uhl, M., Génin, P., Civas, A.,
471 Ryffel, B., Kanellopoulos, J., Tschopp, J., André, F., Lidereau, R., Mclaughlin, N.M., Haynes, N.M.,
472 Smyth, M.J., Kroemer, G., and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in
473 dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. *Nature Medicine* 15,
474 1170.

475 Giner-Casares, J.J., Henriksen-Lacey, M., Coronado-Puchau, M., and Liz-Marzán, L.M. (2016). Inorganic
476 nanoparticles for biomedicine: where materials scientists meet medical research. *Materials*
477 *Today* 19, 19-28.

478 Giri, P.K., Sable, S.B., Verma, I., and Khuller, G.K. (2005). Comparative evaluation of intranasal and
479 subcutaneous route of immunization for development of mucosal vaccine against experimental
480 tuberculosis. *FEMS Immunol Med Microbiol* 45, 87-93.

481 Gomes, A.C., Mohsen, M., and Bachmann, M.F. (2017). Harnessing Nanoparticles for
482 Immunomodulation and Vaccines. *Vaccines (Basel)* 5.

483 Griffin, D. (1997). Economic impact associated with respiratory disease in beef cattle. *Vet Clin North Am*
484 *Food Anim Pract* 13, 367-377.

485 Grohskopf, L.A., Sokolow, L.Z., Olsen, S.J., Bresee, J.S., Broder, K.R., and Karron, R.A. (2015). Prevention
486 and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on
487 Immunization Practices, United States, 2015-16 Influenza Season. *MMWR Morb Mortal Wkly*
488 *Rep* 64, 818-825.

489 Hajj Hussein, I., Chams, N., Chams, S., El Sayegh, S., Badran, R., Raad, M., Gerges-Geagea, A., Leone, A.,
490 and Jurjus, A. (2015). Vaccines Through Centuries: Major Cornerstones of Global Health. *Front*
491 *Public Health* 3, 269.

492 Hall, K., Blair Zajdel, M.E., and Blair, G.E. (2010). Unity and diversity in the human adenoviruses:
493 exploiting alternative entry pathways for gene therapy. *Biochem J* 431, 321-336.

494 Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E.,
495 Moore, K.J., and Golenbock, D.T. (2008). The NALP3 inflammasome is involved in the innate
496 immune response to amyloid- β . *Nature Immunology* 9, 857.

497 He, Y., Hara, H., and Núñez, G. (2016). Mechanism and Regulation of NLRP3 Inflammasome Activation.
498 *Trends in Biochemical Sciences* 41, 1012-1021.

499 Henrickson, K.J. (2003). Parainfluenza viruses. *Clin Microbiol Rev* 16, 242-264.

500 Herve, P.L., Deloizy, C., Descamps, D., Rameix-Welti, M.A., Fix, J., Mclellan, J.S., Eleouet, J.F., and Riffault,
501 S. (2017). RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle
502 RSV vaccine. *Nanomedicine* 13, 411-420.

503 Herve, P.L., Raliou, M., Bourdieu, C., Dubuquoy, C., Petit-Camurdan, A., Bertho, N., Eleouet, J.F.,
504 Chevalier, C., and Riffault, S. (2014). A novel subnucleocapsid nanoplatform for mucosal
505 vaccination against influenza virus that targets the ectodomain of matrix protein 2. *J Virol* 88,
506 325-338.

507 Hiramatsu, H., and Osterloh, F.E. (2004). A Simple Large-Scale Synthesis of Nearly Monodisperse Gold
508 and Silver Nanoparticles with Adjustable Sizes and with Exchangeable Surfactants. *Chemistry of*
509 *Materials* 16, 2509-2511.

510 Hirosue, S., Kourtis, I.C., Van Der Vlies, A.J., Hubbell, J.A., and Swartz, M.A. (2010). Antigen delivery to
511 dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides:
512 Cross-presentation and T cell activation. *Vaccine* 28, 7897-7906.

513 Ichinohe, T., Ainai, A., Tashiro, M., Sata, T., and Hasegawa, H. (2009). PolyI:polyC12U adjuvant-combined
514 intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
515 *Vaccine* 27, 6276-6279.

516 Irvine, D.J., Hanson, M.C., Rakhra, K., and Tokatlian, T. (2015). Synthetic Nanoparticles for Vaccines and
517 Immunotherapy. *Chem Rev* 115, 11109-11146.

518 Islam, S., Bhuiyan, M.a.R., and Islam, M.N. (2016). Chitin and Chitosan: Structure, Properties and
519 Applications in Biomedical Engineering. *Journal of Polymers and the Environment* 25, 854-866.

520 Jazayeri, M.H., Amani, H., Pourfatollah, A.A., Pazoki-Toroudi, H., and Sedighimoghaddam, B. (2016).
521 Various methods of gold nanoparticles (GNPs) conjugation to antibodies. *Sensing and Bio-*
522 *Sensing Research* 9, 17-22.

523 Johnson, K.K., and Pendell, D.L. (2017). Market Impacts of Reducing the Prevalence of Bovine
524 Respiratory Disease in United States Beef Cattle Feedlots. *Front Vet Sci* 4, 189.

525 Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F., and Farokhzad, O.C. (2012). Targeted
526 polymeric therapeutic nanoparticles: design, development and clinical translation. *Chem Soc Rev*
527 41, 2971-3010.

528 Kanekiyo, M., Wei, C.J., Yassine, H.M., Mctamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S., Kong,
529 W.P., Wang, L., and Nabel, G.J. (2013). Self-assembling influenza nanoparticle vaccines elicit
530 broadly neutralizing H1N1 antibodies. *Nature* 499, 102-106.

531 Kang, H., Yan, M., Yu, Q., and Yang, Q. (2014). Characteristics of Nasal-Associated Lymphoid Tissue
532 (NALT) and Nasal Absorption Capacity in Chicken. *PLOS ONE* 8, e84097.

533 Kang, S., Ahn, S., Lee, J., Kim, J.Y., Choi, M., Gujrati, V., Kim, H., Kim, J., Shin, E.C., and Jon, S. (2017).
534 Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-
535 lymphocyte responses. *J Control Release* 256, 56-67.

536 Kanojia, G., Have, R.T., Soema, P.C., Frijlink, H., Amorij, J.P., and Kersten, G. (2017). Developments in the
537 formulation and delivery of spray dried vaccines. *Hum Vaccin Immunother* 13, 2364-2378.

538 Kasturi, S.P., Kozlowski, P.A., Nakaya, H.I., Burger, M.C., Russo, P., Pham, M., Kovalenkov, Y., Silveira,
539 E.L., Havenar-Daughton, C., Burton, S.L., Kilgore, K.M., Johnson, M.J., Nabi, R., Legere, T., Sher,
540 Z.J., Chen, X., Amara, R.R., Hunter, E., Bosinger, S.E., Spearman, P., Crotty, S., Villinger, F.,
541 Derdeyn, C.A., Wrammert, J., and Pulendran, B. (2017). Adjuvanting a Simian Immunodeficiency
542 Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent
543 Antibody Responses and Enhanced Protection in TRIM5alpha Restrictive Macaques. *J Virol* 91.

544 Kharb, S., and Charan, S. (2011). Mucosal immunization provides better protection than subcutaneous
545 immunization against *Pasteurella multocida* (B:2) in mice preimmunized with the outer
546 membrane proteins. *Vet Res Commun* 35, 457-461.

547 Kim, S.H., and Jang, Y.S. (2017). The development of mucosal vaccines for both mucosal and systemic
548 immune induction and the roles played by adjuvants. *Clin Exp Vaccine Res* 6, 15-21.

549 Kishimoto, T.K., and Maldonado, R.A. (2018). Nanoparticles for the Induction of Antigen-Specific
550 Immunological Tolerance. *Front Immunol* 9, 230.

551 Krasia-Christoforou, T., and Georgiou, T.K. (2013). Polymeric theranostics: using polymer-based systems
552 for simultaneous imaging and therapy. *Journal of Materials Chemistry B* 1, 3002.

553 Kumari, A., Singla, R., Guliani, A., and Yadav, S.K. (2014). Nanoencapsulation for drug delivery. *EXCLI J* 13,
554 265-286.

555 Kushnir, N., Streatfield, S.J., and Yusibov, V. (2012). Virus-like particles as a highly efficient vaccine
556 platform: diversity of targets and production systems and advances in clinical development.
557 *Vaccine* 31, 58-83.

558 Kutter, J.S., Spronken, M.I., Fraaij, P.L., Fouchier, R.A., and Herfst, S. (2018). Transmission routes of
559 respiratory viruses among humans. *Curr Opin Virol* 28, 142-151.

560 Lamb, R.A., and Choppin, P.W. (1983). The gene structure and replication of influenza virus. *Annu Rev*
561 *Biochem* 52, 467-506.

562 Lang, R., Winter, G., Vogt, L., Zurcher, A., Dorigo, B., and Schimmele, B. (2009). Rational design of a
563 stable, freeze-dried virus-like particle-based vaccine formulation. *Drug Dev Ind Pharm* 35, 83-97.

564 Laval, J.M., Mazeran, P.E., and Thomas, D. (2000). Nanobiotechnology and its role in the development of
565 new analytical devices. *Analyst* 125, 29-33.

566 Lawson, D.M., Artymiuk, P.J., Yewdall, S.J., Smith, J.M., Livingstone, J.C., Treffry, A., Luzzago, A., Levi, S.,
567 Arosio, P., Cesareni, G., and Et Al. (1991). Solving the structure of human H ferritin by genetically
568 engineering intermolecular crystal contacts. *Nature* 349, 541-544.

569 Lee, L.A., and Wang, Q. (2006). Adaptations of nanoscale viruses and other protein cages for medical
570 applications. *Nanomedicine* 2, 137-149.

571 Lee, Y.T., Ko, E.J., Lee, Y., Kim, K.H., Kim, M.C., Lee, Y.N., and Kang, S.M. (2018). Intranasal vaccination
572 with M2e5x virus-like particles induces humoral and cellular immune responses conferring
573 cross-protection against heterosubtypic influenza viruses. *PLoS One* 13, e0190868.

574 Li, C.Q., Soistman, E., and Carter, D.C. (2006). Ferritin nanoparticle technology... A new platform for
575 antigen presentation and vaccine development. *Industrial Biotechnology* 2, 143-147.

576 Li, P., Tan, H., Xu, D., Yin, F., Cheng, Y., Zhang, X., Liu, Y., and Wang, F. (2014a). Effect and mechanisms of
577 curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant. *Carbohydr*
578 *Polym* 110, 446-455.

579 Li, P., Zhang, X., Cheng, Y., Li, J., Xiao, Y., Zhang, Q., Zong, A., Zhong, C., and Wang, F. (2014b).
580 Preparation and in vitro immunomodulatory effect of curdlan sulfate. *Carbohydr Polym* 102,
581 852-861.

582 Liu, Q., Zheng, X., Zhang, C., Shao, X., Zhang, X., Zhang, Q., and Jiang, X. (2015). Conjugating influenza a
583 (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the
584 immunogenicity of the antigen after nasal administration. *J Med Virol* 87, 1807-1815.

585 Lopez-Sagasetta, J., Malito, E., Rappuoli, R., and Bottomley, M.J. (2016). Self-assembling protein
586 nanoparticles in the design of vaccines. *Comput Struct Biotechnol J* 14, 58-68.

587 Lu, M.P., Ma, L.Y., Zheng, Q., Dong, L.L., and Chen, Z.M. (2013). Clinical characteristics of adenovirus
588 associated lower respiratory tract infection in children. *World J Pediatr* 9, 346-349.

589 Lycke, N. (2012). Recent progress in mucosal vaccine development: potential and limitations. *Nat Rev*
590 *Immunol* 12, 592-605.

591 Lynn, G.M., Laga, R., Darrah, P.A., Ishizuka, A.S., Balaci, A.J., Dulcey, A.E., Pechar, M., Pola, R., Gerner,
592 M.Y., Yamamoto, A., Buechler, C.R., Quinn, K.M., Smelkinson, M.G., Vanek, O., Cawood, R., Hills,
593 T., Vasalatiy, O., Kastenmüller, K., Francica, J.R., Stutts, L., Tom, J.K., Ryu, K.A., Esser-Kahn, A.P.,
594 Etrych, T., Fisher, K.D., Seymour, L.W., and Seder, R.A. (2015). In vivo characterization of the
595 physicochemical properties of polymer-linked TLR agonists that enhance vaccine
596 immunogenicity. *Nature Biotechnology* 33, 1201.

597 Mahapatro, A., and Singh, D.K. (2011). Biodegradable nanoparticles are excellent vehicle for site
598 directed in-vivo delivery of drugs and vaccines. *J Nanobiotechnology* 9, 55.

599 Mamo, T., and Poland, G.A. (2012). Nanovaccinology: the next generation of vaccines meets 21st
600 century materials science and engineering. *Vaccine* 30, 6609-6611.

601 Mansoor, F., Earley, B., Cassidy, J.P., Markey, B., Doherty, S., and Welsh, M.D. (2015). Comparing the
602 immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V
603 vaccine in dairy calves. *BMC Vet Res* 11, 220.

604 Mapletoft, J.W., Latimer, L., Babiuk, L.A., and Van Drunen Littel-Van Den Hurk, S. (2010). Intranasal
605 Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior
606 Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of
607 Intranasal and Subcutaneous Prime-Boost Strategies. *Clinical and Vaccine Immunology* 17, 23.

608 Marasini, N., Giddam, A.K., Khalil, Z.G., Hussein, W.M., Capon, R.J., Batzloff, M.R., Good, M.F., Toth, I.,
609 and Skwarczynski, M. (2016). Double adjuvanting strategy for peptide-based vaccines: trimethyl
610 chitosan nanoparticles for lipopeptide delivery. *Nanomedicine (Lond)* 11, 3223-3235.

611 Marasini, N., Skwarczynski, M., and Toth, I. (2017). Intranasal delivery of nanoparticle-based vaccines.
612 *Ther Deliv* 8, 151-167.

613 Marques Neto, L.M., Kipnis, A., and Junqueira-Kipnis, A.P. (2017). Role of Metallic Nanoparticles in
614 Vaccinology: Implications for Infectious Disease Vaccine Development. *Front Immunol* 8, 239.

615 Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Franchi, L.,
616 Yoshihara, E., Chen, Z., Mullooly, N., Mielke, L.A., Harris, J., Coll, R.C., Mills, K.H.G., Mok, K.H.,
617 Newsholme, P., Nuñez, G., Yodoi, J., Kahn, S.E., Lavelle, E.C., and O'Neill, L.A.J. (2010). Activation
618 of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced
619 IL-1 β in type 2 diabetes. *Nature Immunology* 11, 897.

620 Mathieu, C., Rioux, G., Dumas, M.C., and Leclerc, D. (2013). Induction of innate immunity in lungs with
621 virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae
622 challenge. *Nanomedicine* 9, 839-848.

623 Mazur, N.I., Higgins, D., Nunes, M.C., Melero, J.A., Langedijk, A.C., Horsley, N., Buchholz, U.J., Openshaw,
624 P.J., McLellan, J.S., Englund, J.A., Mejias, A., Karron, R.A., Simoes, E.A., Knezevic, I., Ramilo, O.,
625 Piedra, P.A., Chu, H.Y., Falsey, A.R., Nair, H., Kragten-Tabatabaie, L., Greenough, A., Baraldi, E.,
626 Papadopoulos, N.G., Vekemans, J., Polack, F.P., Powell, M., Satav, A., Walsh, E.E., Stein, R.T.,
627 Graham, B.S., Bont, L.J., and Respiratory Syncytial Virus Network, F. (2018). The respiratory
628 syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. *Lancet*
629 *Infect Dis* 18, e295-e311.

630 McCormick, A.A., Shakeel, A., Yi, C., Kaur, H., Mansour, A.M., and Bakshi, C.S. (2018). Intranasal
631 administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully
632 protects mice against Francisella tularensis LVS challenge. *PLoS One* 13, e0194614.

633 McGill, J.L., Kelly, S.M., Kumar, P., Speckhart, S., Haughney, S.L., Henningson, J., Narasimhan, B., and
634 Sacco, R.E. (2018). Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial
635 virus infection in the neonatal calf. *Sci Rep* 8, 3021.

636 Mohsen, M.O., Zha, L., Cabral-Miranda, G., and Bachmann, M.F. (2017). Major findings and recent
637 advances in virus-like particle (VLP)-based vaccines. *Semin Immunol* 34, 123-132.

638 Mora-Solano, C., Wen, Y., Han, H., Chen, J., Chong, A.S., Miller, M.L., Pompano, R.R., and Collier, J.H.
639 (2017). Active immunotherapy for TNF-mediated inflammation using self-assembled peptide
640 nanofibers. *Biomaterials* 149, 1-11.

641 Negahdaripour, M., Golkar, N., Hajighahramani, N., Kianpour, S., Nezafat, N., and Ghasemi, Y. (2017).
642 Harnessing self-assembled peptide nanoparticles in epitope vaccine design. *Biotechnol Adv* 35,
643 575-596.

644 Niemi, K., Teirila, L., Lappalainen, J., Rajamaki, K., Baumann, M.H., Oorni, K., Wolff, H., Kovanen, P.T.,
645 Matikainen, S., and Eklund, K.K. (2011). Serum amyloid A activates the NLRP3 inflammasome via
646 P2X7 receptor and a cathepsin B-sensitive pathway. *J Immunol* 186, 6119-6128.

647 Niu, Y., Yu, M., Hartono, S.B., Yang, J., Xu, H., Zhang, H., Zhang, J., Zou, J., Dexter, A., Gu, W., and Yu, C.
648 (2013). Nanoparticles mimicking viral surface topography for enhanced cellular delivery. *Adv*
649 *Mater* 25, 6233-6237.

650 Okamoto, S., Matsuura, M., Akagi, T., Akashi, M., Tanimoto, T., Ishikawa, T., Takahashi, M., Yamanishi,
651 K., and Mori, Y. (2009). Poly(γ -glutamic acid) nano-particles combined with mucosal
652 influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. *Vaccine*
653 27, 5896-5905.

654 Pachioni-Vasconcelos Jde, A., Lopes, A.M., Apolinario, A.C., Valenzuela-Oses, J.K., Costa, J.S., Nascimento
655 Lde, O., Pessoa, A., Barbosa, L.R., and Rangel-Yagui Cde, O. (2016). Nanostructures for protein
656 drug delivery. *Biomater Sci* 4, 205-218.

657 Pan, J., Wang, Y., Zhang, C., Wang, X., Wang, H., Wang, J., Yuan, Y., Wang, X., Zhang, X., Yu, C., Sun, S.-K.,
658 and Yan, X.-P. (2018). Antigen-Directed Fabrication of a Multifunctional Nanovaccine with
659 Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy. *Advanced*
660 *Materials* 30, 1704408.

661 Papadopoulos, N.G., Megremis, S., Kitsioulis, N.A., Vangelatou, O., West, P., and Xepapadaki, P. (2017).
662 Promising approaches for the treatment and prevention of viral respiratory illnesses. *J Allergy*
663 *Clin Immunol* 140, 921-932.

664 Park, H.-J., Lee, E.-Y., Jung, S., Ko, H.L., Lee, S.-M., and Nam, J.-H. (2017). Spike nanoparticle and
665 recombinant adenovirus 5 vaccines induce specific antibodies against the Middle East
666 respiratory syndrome coronavirus (MERS-CoV). *The Journal of Immunology* 198, 225-225.

667 Parveen, K., Banse, V., and Ledwani, L. (2016). Green synthesis of nanoparticles: Their advantages and
668 disadvantages. *AIP Conference Proceedings* 1249, 020048.

669 Pavia, A.T. (2011). Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of
670 diagnosis. *Clin Infect Dis* 52 Suppl 4, S284-289.

671 Pensa, E., Cortes, E., Corthey, G., Carro, P., Vericat, C., Fonticelli, M.H., Benitez, G., Rubert, A.A., and
672 Salvarezza, R.C. (2012). The chemistry of the sulfur-gold interface: in search of a unified model.
673 *Acc Chem Res* 45, 1183-1192.

674 Petersen, L.K., Phanse, Y., Ramer-Tait, A.E., Wannemuehler, M.J., and Narasimhan, B. (2012).
675 Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. *Mol*
676 *Pharm* 9, 874-882.

677 Piluso, S., Soutan, A.H., and Patterson, J. (2017). Molecularly Engineered Polymer-Based Systems in
678 Drug Delivery and Regenerative Medicine. *Curr Pharm Des* 23, 281-294.

679 Qi, M., Zhang, X.E., Sun, X., Zhang, X., Yao, Y., Liu, S., Chen, Z., Li, W., Zhang, Z., Chen, J., and Cui, Z.
680 (2018). Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection. *Small*
681 14, e1703207.

682 Quan, F.S., Huang, C., Compans, R.W., and Kang, S.M. (2007). Virus-like particle vaccine induces
683 protective immunity against homologous and heterologous strains of influenza virus. *J Virol* 81,
684 3514-3524.

685 Rahimian, S., Kleinovink, J.W., Fransen, M.F., Mezzanotte, L., Gold, H., Wisse, P., Overkleeft, H., Amidi,
686 M., Jiskoot, W., Lowik, C.W., Ossendorp, F., and Hennink, W.E. (2015). Near-infrared labeled,
687 ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In
688 vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response. *Biomaterials* 37,
689 469-477.

690 Ross, K.A., Haughney, S.L., Petersen, L.K., Boggiatto, P., Wannemuehler, M.J., and Narasimhan, B. (2014).
691 Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48
692 hours. *Adv Healthc Mater* 3, 1071-1077.

693 Roux, X., Dubuquoy, C., Durand, G., Tran-Tolla, T.L., Castagne, N., Bernard, J., Petit-Camurdan, A.,
694 Eleouet, J.F., and Riffault, S. (2008). Sub-nucleocapsid nanoparticles: a nasal vaccine against
695 respiratory syncytial virus. *PLoS One* 3, e1766.

696 Sahdev, P., Ochyl, L.J., and Moon, J.J. (2014). Biomaterials for Nanoparticle Vaccine Delivery Systems.
697 *Pharmaceutical Research* 31, 2563-2582.

698 Salazar-Gonzalez, J.A., Gonzalez-Ortega, O., and Rosales-Mendoza, S. (2015). Gold nanoparticles and
699 vaccine development. *Expert Rev Vaccines* 14, 1197-1211.

700 Santos, D.M., Carneiro, M.W., De Moura, T.R., Soto, M., Luz, N.F., Prates, D.B., Irache, J.M., Brodskyn, C.,
701 Barral, A., Barral-Netto, M., Espuelas, S., Borges, V.M., and De Oliveira, C.I. (2013). PLGA
702 nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of
703 Leishmania. *Nanomedicine* 9, 985-995.

704 Sawaengsak, C., Mori, Y., Yamanishi, K., Mitrevej, A., and Sinchaipanid, N. (2014). Chitosan nanoparticle
705 encapsulated hemagglutinin-split influenza virus mucosal vaccine. *AAPS PharmSciTech* 15, 317-
706 325.

707 Scharf, B., Clement, C.C., Wu, X.X., Morozova, K., Zanolini, D., Follenzi, A., Larocca, J.N., Levon, K.,
708 Sutterwala, F.S., Rand, J., Cobelli, N., Purdue, E., Hajjar, K.A., and Santambrogio, L. (2012).
709 Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris.
710 *Nat Commun* 3, 755.

711 Scheerlinck, J.P., and Greenwood, D.L. (2008). Virus-sized vaccine delivery systems. *Drug Discov Today*
712 13, 882-887.

713 Schneider-Ohrum, K., and Ross, T.M. (2012). "Virus-Like Particles for Antigen Delivery at Mucosal
714 Surfaces," in *Mucosal Vaccines: Modern Concepts, Strategies, and Challenges*, ed. P.A.
715 Kozlowski. (Berlin, Heidelberg: Springer Berlin Heidelberg), 53-73.

716 Schneider, C.S., Xu, Q., Boylan, N.J., Chisholm, J., Tang, B.C., Schuster, B.S., Henning, A., Ensign, L.M., Lee,
717 E., Adstamongkonkul, P., Simons, B.W., Wang, S.S., Gong, X., Yu, T., Boyle, M.P., Suk, J.S., and
718 Hanes, J. (2017). Nanoparticles that do not adhere to mucus provide uniform and long-lasting
719 drug delivery to airways following inhalation. *Sci Adv* 3, e1601556.

720 Seo, Y.B., Song, J.Y., Choi, M.J., Kim, I.S., Yang, T.U., Hong, K.W., Cheong, H.J., and Kim, W.J. (2014).
721 Etiology and clinical outcomes of acute respiratory virus infection in hospitalized adults. *Infect*
722 *Chemother* 46, 67-76.

723 Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., and Santamaria, P. (2015). Nanoparticle-
724 Based Immunotherapy for Cancer. *ACS Nano* 9, 16-30.

725 Sharp, F.A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'hagan, D.T., Petrilli, V.,
726 Tschoop, J., O'neill, L.A., and Lavelle, E.C. (2009). Uptake of particulate vaccine adjuvants by
727 dendritic cells activates the NALP3 inflammasome. *Proc Natl Acad Sci U S A* 106, 870-875.

728 Si, Y., Wen, Y., Kelly, S.H., Chong, A.S., and Collier, J.H. (2018). Intranasal delivery of adjuvant-free
729 peptide nanofibers elicits resident CD8(+) T cell responses. *J Control Release* 282, 120-130.

730 Silva, A.L., Soema, P.C., Slutter, B., Ossendorp, F., and Jiskoot, W. (2016). PLGA particulate delivery
731 systems for subunit vaccines: Linking particle properties to immunogenicity. *Hum Vaccin*
732 *Immunother* 12, 1056-1069.

733 Spampinato, V., Parracino, M.A., La Spina, R., Rossi, F., and Ceccone, G. (2016). Surface Analysis of Gold
734 Nanoparticles Functionalized with Thiol-Modified Glucose SAMs for Biosensor Applications.
735 *Front Chem* 4, 8.

736 Szeto, G.L., and Lavik, E.B. (2016). Materials design at the interface of nanoparticles and innate
737 immunity. *J Mater Chem B* 4, 1610-1618.

738 Tai, W., Roberts, L., Seryshev, A., Gubatan, J.M., Bland, C.S., Zabriskie, R., Kulkarni, S., Soong, L.,
739 Mbawuike, I., Gilbert, B., Kheradmand, F., and Corry, D.B. (2011). Multistrain influenza
740 protection induced by a nanoparticulate mucosal immunotherapeutic. *Mucosal Immunol* 4, 197-
741 207.

742 Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B.S., Chu, B., and Chen, X. (2016). Polymeric nanostructured
743 materials for biomedical applications. *Progress in Polymer Science* 60, 86-128.

744 Tao, W., Hurst, B.L., Shakya, A.K., Uddin, M.J., Ingrole, R.S., Hernandez-Sanabria, M., Arya, R.P., Bimler,
745 L., Paust, S., Tabet, E.B., and Gill, H.S. (2017). Consensus M2e peptide conjugated to gold
746 nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. *Antiviral Res*
747 141, 62-72.

748 Tao, W., Ziemer, K.S., and Gill, H.S. (2014). Gold nanoparticle-M2e conjugate coformulated with CpG
749 induces protective immunity against influenza A virus. *Nanomedicine (Lond)* 9, 237-251.

750 Taylor, J.D., Fulton, R.W., Lehenbauer, T.W., Step, D.L., and Confer, A.W. (2010). The epidemiology of
751 bovine respiratory disease: What is the evidence for predisposing factors? *The Canadian*
752 *Veterinary Journal* 51, 1095-1102.

753 Therien, A., Bedard, M., Carignan, D., Rioux, G., Gauthier-Landry, L., Laliberte-Gagne, M.E., Bolduc, M.,
754 Savard, P., and Leclerc, D. (2017). A versatile papaya mosaic virus (PapMV) vaccine platform
755 based on sortase-mediated antigen coupling. *J Nanobiotechnology* 15, 54.

756 Tschopp, J., and Schroder, K. (2010). NLRP3 inflammasome activation: the convergence of multiple
757 signalling pathways on ROS production? *Nature Reviews Immunology* 10, 210.

758 Ulery, B.D., Kumar, D., Ramer-Tait, A.E., Metzger, D.W., Wannemuehler, M.J., and Narasimhan, B.
759 (2011a). Design of a protective single-dose intranasal nanoparticle-based vaccine platform for
760 respiratory infectious diseases. *PLoS One* 6, e17642.

761 Ulery, B.D., Petersen, L.K., Phanse, Y., Kong, C.S., Broderick, S.R., Kumar, D., Ramer-Tait, A.E., Carrillo-
762 Conde, B., Rajan, K., Wannemuehler, M.J., Bellaire, B.H., Metzger, D.W., and Narasimhan, B.
763 (2011b). Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. *Sci Rep*
764 1, 198.

765 Ulery, B.D., Phanse, Y., Sinha, A., Wannemuehler, M.J., Narasimhan, B., and Bellaire, B.H. (2009).
766 Polymer chemistry influences monocytic uptake of polyanhydride nanospheres. *Pharm Res* 26,
767 683-690.

768 Utlely, T.J., Ducharme, N.A., Varthakavi, V., Shepherd, B.E., Santangelo, P.J., Lindquist, M.E., Goldenring,
769 J.R., and Crowe, J.E., Jr. (2008). Respiratory syncytial virus uses a Vps4-independent budding
770 mechanism controlled by Rab11-FIP2. *Proc Natl Acad Sci U S A* 105, 10209-10214.

771 Vartak, A., and Sucheck, S.J. (2016). Recent Advances in Subunit Vaccine Carriers. *Vaccines (Basel)* 4, 12.

772 Vela-Ramirez, J.E., Goodman, J.T., Boggiatto, P.M., Roychoudhury, R., Pohl, N.L., Hostetter, J.M.,
773 Wannemuehler, M.J., and Narasimhan, B. (2015). Safety and biocompatibility of carbohydrate-
774 functionalized polyanhydride nanoparticles. *AAPS J* 17, 256-267.

775 Walker, T.A., Khurana, S., and Tilden, S.J. (1994). Viral respiratory infections. *Pediatr Clin North Am* 41,
776 1365-1381.

777 Wang, C., Zhu, W., Luo, Y., and Wang, B.Z. (2018). Gold nanoparticles conjugating recombinant influenza
778 hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. *Nanomedicine* 14,
779 1349-1360.

780 Wee, J.L., Scheerlinck, J.P., Snibson, K.J., Edwards, S., Pearce, M., Quinn, C., and Sutton, P. (2008).
781 Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal
782 immunity with antigen dose sparing. *Mucosal Immunol* 1, 489-496.

783 Woodrow, K.A., Bennett, K.M., and Lo, D.D. (2012). Mucosal vaccine design and delivery. *Annu Rev*
784 *Biomed Eng* 14, 17-46.

785 World Health Organization (2016). Top 10 global causes of deaths.

786 World Health Organization (2018). Influenza (Seasonal).

787 Wu, M., Zhao, H., Li, M., Yue, Y., Xiong, S., and Xu, W. (2017). Intranasal Vaccination with Mannosylated
788 Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the
789 Lungs of Mice and Improves Protection against Pulmonary Mycobacterial Challenge. *Front Cell*
790 *Infect Microbiol* 7, 445.

791 Yamashita, I., Iwahori, K., and Kumagai, S. (2010). Ferritin in the field of nanodevices. *Biochim Biophys*
792 *Acta* 1800, 846-857.

793 Yang, S., Wang, T., Bohon, J., Gagne, M.E., Bolduc, M., Leclerc, D., and Li, H. (2012). Crystal structure of
794 the coat protein of the flexible filamentous papaya mosaic virus. *J Mol Biol* 422, 263-273.

795 Zeltins, A. (2013). Construction and characterization of virus-like particles: a review. *Mol Biotechnol* 53,
796 92-107.

797 Zhang, S., Huang, S., Lu, L., Song, X., Li, P., and Wang, F. (2018). Curdlan sulfate-O-linked quaternized
798 chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous
799 antigens via intranasal vaccination. *Int J Nanomedicine* 13, 2377-2394.

800 Zhao, Q., Li, S., Yu, H., Xia, N., and Modis, Y. (2013). Virus-like particle-based human vaccines: quality
801 assessment based on structural and functional properties. *Trends Biotechnol* 31, 654-663.

802 Zhu, M., Wang, R., and Nie, G. (2014). Applications of nanomaterials as vaccine adjuvants. *Hum Vaccin*
803 *Immunother* 10, 2761-2774.

804 Zilker, C., Kozlova, D., Sokolova, V., Yan, H., Epple, M., Überla, K., and Temchura, V. (2017). Nanoparticle-
805 based B-cell targeting vaccines: Tailoring of humoral immune responses by functionalization
806 with different TLR-ligands. *Nanomedicine: Nanotechnology, Biology and Medicine* 13, 173-182.

807 Zuercher, A.W., Coffin, S.E., Thurnheer, M.C., Fundova, P., and Cebra, J.J. (2002). Nasal-Associated
808 Lymphoid Tissue Is a Mucosal Inductive Site for Virus-Specific Humoral and Cellular Immune
809 Responses. *The Journal of Immunology* 168, 1796.

810


811

812

813

814

815



816

817 **Figure 1:** Overview of the immune response in the upper respiratory tract. **A)** Schematic view of
 818 different nanoparticles used for intranasal vaccination. **B)** Mechanisms of NALTs immune
 819 responses in the upper respiratory tract. **(1)** Nanoparticles are transcytosed from the mucus layer
 820 into the nasal epithelial tissues by microfold cells (M cells) or passively diffuse through epithelial
 821 cell junctions. **(2)** Other nanoparticles are captured and internalized by DCs (dendritic cells) from
 822 their extension through epithelial junctions and by other APCs, such as B cells. **(3)** Cells that have
 823 encountered nanoparticles migrate to the nearest lymph node in order to activate naive T helper
 824 cells. Once activated, T helper cells activate B cells that have encountered the same antigen
 825 presented by nanoparticles. Activated B cells proliferate in the lymph node (B cell zone) and, once
 826 mature, enter systemic circulation in order to reach the inflammation site. IgA+ B cells locally
 827 differentiate into antibody-secreting plasma cells to produce IgA dimers. **(4)** IgA dimers are
 828 secreted via polymeric Ig receptor (pIgR) at the mucosal surface. NALT immune response induces
 829 long-lasting memory B and T cells able to trigger a rapid recall response.

830

831

Table 1: Nanoparticle-based vaccines against respiratory viruses delivered via the intranasal route.

832

Material	Size (nm)	Virus	Antigen/epitope	Adjuvant	Reference
Polymeric nanoparticles					
PLGA	225.4	Bovine parainfluenza 3 virus (BPI3V)	BPI3V proteins	-	(Mansoor et al., 2015)
	200 - 300	Swine influenza virus (H1N2)	Inactivated virus H1N2 antigen	-	(Dhakal et al., 2017)
γ -PGA ^a	100 - 200	Influenza (H1N1)	Hemagglutinin	-	(Okamoto et al., 2009)
Chitosan	140	Influenza (H1N1)	H1N1 antigen	-	(Liu et al., 2015)
	300 - 350	Influenza (H1N1)	HA-Split	-	(Sawaengsak et al., 2014)
	571.7	Swine influenza virus (H1N2)	Killed swine influenza antigen	-	(Dhakal et al., 2018)
	200 - 250	Influenza (H1N1)	M2e	Heat shock protein 70c	(Dabaghian et al., 2018)
HPMA/NIPAM	12-25	RSV	F protein	TLR-7/8 agonist	(Francica et al., 2016), (Lynn et al., 2015)
Polyanhydride	200 - 800	RSV	F and G glycoproteins	-	(McGill et al., 2018), (Ulery et al., 2009)
Self-assembling proteins and peptide-based nanoparticles					
N nucleocapside protein of RSV	15	RSV	RSV phosphoprotein	R192G	(Roux et al., 2008)
	15	RSV	FsII	Montanide™ Gel 01	(Herve et al., 2017)
	15	Influenza (H1N1)	M2e	Montanide™ Gel 01	(Herve et al., 2014)
Ferritin	12.5	Influenza (H1N1)	M2e	-	(Qi et al., 2018)
Q11	-	Influenza (H1N1)	Acid polymerase	-	(Si et al., 2018)
Inorganic nanoparticles					
Gold	12	Influenza	M2e	CpG	(Tao et al., 2017)
Others					
VLP	80 - 120	Influenza (H1N1)	Hemagglutinin	-	(Quan et al., 2007)
	80 - 120	Influenza (H1N1, H3N2, H5N1)	M2e	-	(Lee et al., 2018)
	80 - 120	RSV	F protein et G glycoprotein of RSV and M1 protein of Influenza	-	(Cai et al., 2017)
ISCOM ^b	40	Influenza (H1N1)	Hemagglutinin	ISCOMATRIX	(Wee et al., 2008), (Coulter et al., 2003)
DLPC liposomes ^c	30-100	Influenza (H1N1)	M2, HA, NP	MPL and trehalose 6,6' dimycolate	(Tai et al., 2011)

833

^a Poly- γ -glutamic acid

834

^b Quillaia saponin, cholesterol, phospholipid and associated antigen

835

^c Dilaurylphosphatidylcholine liposomes